|
Volumn 26, Issue 9, 2008, Pages 981-983
|
Cost/success projections for US biodefense countermeasure development
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTHRAX ANTITOXIN;
ANTHRAX VACCINE;
ANTIBIOTIC AGENT;
ANTITOXIN;
ANTIVIRUS AGENT;
FILOVIRUS VACCINE;
UNCLASSIFIED DRUG;
VIRUS VACCINE;
BIOLOGICAL WARFARE;
BUDGET;
CALCULATION;
COST BENEFIT ANALYSIS;
COST EFFECTIVENESS ANALYSIS;
DRUG APPROVAL;
FUNDING;
GOVERNMENT;
INVESTMENT;
LAW;
LETTER;
MEDICAL RESEARCH;
MONEY;
PRIORITY JOURNAL;
PROBABILITY;
PROTECTION;
PUBLIC HEALTH SERVICE;
UNITED STATES;
BIOTECHNOLOGY;
BIOTERRORISM;
CIVIL DEFENSE;
DISASTER PLANNING;
DRUG INDUSTRY;
PROBABILITY;
RESEARCH;
SECURITY MEASURES;
UNITED STATES;
UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES;
VACCINES;
|
EID: 51349157514
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0908-981 Document Type: Letter |
Times cited : (13)
|
References (8)
|